NVIDIA and Eli Lilly have established a groundbreaking AI co-innovation lab designed to revolutionize the process of discovering new medicines. The partnership will see both companies invest up to $1 billion over five years in infrastructure, research, and talent, with the goal of leveraging artificial intelligence to tackle some of the most complex challenges in pharmaceutical development.
Based in South San Francisco, the lab will bring together Lilly's deep expertise in biology, medicine, and manufacturing with NVIDIA's leadership in AI, accelerated computing, and large-scale data processing. The initiative is built upon NVIDIA's BioNeMo platform and the upcoming Vera Rubin architecture, creating a foundation for next-generation AI models that can analyze vast biological and chemical datasets with unprecedented speed and accuracy.
One of the lab's key focuses will be developing a continuous learning system that integrates Lilly's physical 'wet labs' with computational 'dry labs.' This hybrid approach enables 24/7 AI-assisted experimentation, where data generation from real-world experiments continuously informs and refines AI models. The result is a feedback loop that accelerates the discovery process, allowing researchers to explore billions of potential drug candidates virtually before any physical synthesis occurs.
The collaboration also extends beyond traditional drug discovery. NVIDIA's Omniverse libraries and RTX PRO servers will enable Lilly to create digital twins of its manufacturing lines, allowing for real-time modeling and optimization of production processes. This capability could significantly enhance supply chain reliability and the production of high-demand medications, addressing longstanding challenges in pharmaceutical logistics.
Both companies have previously demonstrated their commitment to AI-driven innovation. Lilly's recently announced AI supercomputer is already one of the most powerful in the industry, while NVIDIA's Clara suite provides open foundation models for life sciences applications. The new co-innovation lab builds on these efforts, aiming to create a blueprint for future drug discovery that combines cutting-edge computing with scientific rigor.
For NVIDIA, this partnership reinforces its role as a leader in AI infrastructure and its growing influence in the life sciences sector. The company's Inception program, which supports startups with technical mentorship and compute resources, will also benefit from the lab's expertise. Meanwhile, Lilly gains access to NVIDIA's advanced architectures and model-building capabilities, potentially unlocking breakthroughs that would be difficult or impossible to achieve independently.
The lab is expected to begin operations early this year, marking a significant step toward integrating AI more deeply into every stage of drug development—from initial discovery to clinical trials and manufacturing. If successful, the initiative could redefine how pharmaceutical companies approach research, potentially reducing the time and cost required to bring new therapies to market while expanding the scope of treatable diseases.
